|
1）Seyama K, Kumasaka T, Kurihara M, et al. Lymphangioleiomyomatosis: adisease involving the lymphatic system. Lymphat Res Biol. 2010; 8: 21-31
|
|
|
|
2）林田美江，藤本圭作，久保惠嗣，他. 肺リンパ脈管筋腫症に関する全国疫学調査，追跡調査および第２回目全国横断調査. 厚生労働省難治性疾患呼吸不全に関する調査研究. 平成19年度総括・分担研究報告書. 2008. p.37
|
|
|
|
|
|
3）林田美江，藤本圭作，久保惠嗣，他．リンパ脈管筋腫症lymphangioleiomyomatosis（LAM）の治療と管理の手引き. 日呼吸会誌．2008; 46: 428-31
|
|
|
|
|
|
4）McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364: 1595-606
|
|
|
|
|
|
5）ノーベルファーマ社のラパリムス製品サイト．http://rapalimus.jp/
|
|
|
|
|
|
6）Ingelfinger JR, Drazen JM. Patient organizations and research on rare diseases. N Engl J Med. 2011; 364: 1670-1
|
|
|
|
|
|
7）Yang Q, Guan KL. Expanding mTOR signaling. Cell Res. 2007; 17: 666-81
|
|
|
|
|
|
8）Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyoma-tosis treated with sirolimus. Ann Intern Med. 2011; 154: 797-805
|
|
|
|
|
|
9）Yao J, Taveira-DaSilva AM, Jones AM, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014; 190: 1273-82
|
|
|
|
|
|
10）Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011; 17: 4071-81
|
|
|
|
|
|
11）Neurohr C, Hoffmann AL, Huppmann P, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir Res. 2011; 12: 66
|
|
|
|
|
|
12）Peces R, Cuesta-López E, Peces C, et al. Giant bilateral renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin. Scientific World Journal. 2011; 11: 2115-23
|
|
|
|
|
|
13）Ando K, Kurihara M, Kataoka H, et al. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig. 2013; 51: 175-83
|
|
|
|
|
14）Suina K, Hayashi T, Mitani K, et al. What’s the role of sirolimus on the treatment of lymphangioleiomyomatosis （LAM）?: merely tuning up of LAM-associated dysfunctional lymphatic vessels rather than cytoreduction? Respir Investig. 2014; 52: 274-6
|
|
|
|
|